Please try another search
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company’s lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.
Name | Age | Since | Title |
---|---|---|---|
Caroline J. Loew | 53 | 2023 | President, CEO & Director |
Benjamin J. Hickey | 49 | 2023 | Independent Director |
Susan Altschuller | 42 | 2023 | Independent Director |
Francis M. Cuss | 69 | 2023 | Independent Director |
Scott T. Jackson | 59 | 2023 | Independent Chairman of the Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review